We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
OGT Grants Exclusive Option to its Tridend Technology to Masstag Technologies Ltd.
News

OGT Grants Exclusive Option to its Tridend Technology to Masstag Technologies Ltd.

OGT Grants Exclusive Option to its Tridend Technology to Masstag Technologies Ltd.
News

OGT Grants Exclusive Option to its Tridend Technology to Masstag Technologies Ltd.

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "OGT Grants Exclusive Option to its Tridend Technology to Masstag Technologies Ltd."

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Oxford Gene Technology (OGT) has announced that it has agreed to grant an exclusive option to licence the technology developed by its former Tridend business Unit to MassTag Technologies Ltd. (MassTag), a biotechnology company developing molecular tools for the research and biotechnology market.

The option will convert to an exclusive licence subject to MassTag successfully concluding its current capital raising.  Under the terms of the licence, OGT will become a minority shareholder in MassTag.

Mike Evans, CEO at OGT said: “Following a strategic review, OGT decided to focus its efforts in the field of microarrays and sought partners capable of maximising the value from the Tridend business unit products and intellectual property.  We are pleased to announce that we have found a partner who, we believe, has the right qualities and expertise to successfully exploit the products.”

John Thornback, CEO and Co-Founder of MassTag stated: "We are excited by the wide range of possible applications of the Tridend technology.  The extensive intellectual property package opens up a large number of different product lines and markets.  As we are focused on the research and non clinical markets we can bring these products to market quickly and cost effectively."

Advertisement